Inventory / revenue moved 1545 bp higher
Inventory / revenue changed +1545 basis points from the comparable as-filed period.
62.15%→77.61%3 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →IRIX financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Operating income decreased 9.5%
Operating income changed -9.5% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
-$940,000→-$1.0M3 prior comparisons
Capital expenditure increased 284.6%
Capital expenditure changed +284.6% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes.
$13,000→$50,0004 prior comparisons
Free-cash-flow margin moved 401 bp higher
Free-cash-flow margin changed +401 basis points from the comparable as-filed period.
-3.02%→0.99%3 prior comparisons
Operating cash-flow margin moved 431 bp higher
Operating cash-flow margin changed +431 basis points from the comparable as-filed period.
-2.93%→1.38%3 prior comparisons
Working capital decreased 18.0%
Working capital changed -18.0% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$13.2M→$10.8M4 prior comparisons
Gross margin moved 31 bp lower
Gross margin changed -31 basis points from the comparable as-filed period.
34.50%→34.19%3 prior comparisons
Receivables / revenue moved 744 bp lower
Receivables / revenue changed -744 basis points from the comparable as-filed period.
52.59%→45.15%3 prior comparisons
Working capital / assets moved 210 bp lower
Working capital / assets changed -210 basis points from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
41.66%→39.57%4 prior comparisons
Revenue decreased 7.4%
Revenue changed -7.4% from the comparable as-filed period.
$13.6M→$12.6M3 prior comparisons
Total assets decreased 13.7%
Total assets changed -13.7% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$31.6M→$27.3M4 prior comparisons
Research & development increased 7.5%
Research & development changed +7.5% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
$871,000→$936,0003 prior comparisons
Current assets decreased 10.8%
Current assets changed -10.8% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
$26.9M→$24.0M4 prior comparisons
Stock-based compensation decreased 17.5%
Stock-based compensation changed -17.5% from the comparable as-filed period.
$257,000→$212,0003 prior comparisons
R&D / revenue moved 103 bp higher
R&D / revenue changed +103 basis points from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
6.42%→7.45%3 prior comparisons
Gross profit decreased 8.2%
Gross profit changed -8.2% from the comparable as-filed period.
$4.7M→$4.3M3 prior comparisons
Capex / revenue moved 30 bp higher
Capex / revenue changed +30 basis points from the comparable as-filed period.
0.10%→0.40%3 prior comparisons
SBC / revenue moved 21 bp lower
SBC / revenue changed -21 basis points from the comparable as-filed period.
1.89%→1.69%3 prior comparisons
Current liabilities decreased 3.9%
Current liabilities changed -3.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes.
$13.7M→$13.2M4 prior comparisons
Current ratio decreased 7.2%
Current ratio changed -7.2% from the comparable as-filed period. The change ranks at the 25th percentile of 4 prior comparable changes.
1.96→1.824 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.